Kyowa Kirin Co (KYKOY) Fair Value & Analysis
Healthcare · US · Market cap $8.2B
Kyowa Kirin Co
KYKOY · US
Fair value as of: Jul 17, 2026
From 24 valuation models · updated 24 days ago
Fair value updated Jul 17, 2026, revised from $16.26 to $15.88 (−2.3%) since Jun 24, 2026. Share price −1.5% over the past month.
A solid business, currently priced close to our fair value.
What matters now
- The price sits close to our fair value, market and models broadly agree here, little valuation tension.
- A fairly wide model range ($9.18 to $19.85) leaves room in how you read the outcome.
Price vs Fair Value (3 years)
White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Jul 17, 2026.
How to read this chart
34‑month range $12.95 – $19.10 · fair‑value band $9.18 – $19.85 · the $16.00 price screens above the $15.88 fair value. Dashed = 300-day average. As of Jul 17, 2026.
Analysis
Kyowa Kirin Co (KYKOY) currently trades at $16.00, while our model-based Fair Value estimate is $15.88, implying the stock looks roughly 0.8% fairly valued today. The Quality Score stands at 58/100 (solid quality), in the Healthcare sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium, the entry price still matters most (evidence: high).
Over the trailing twelve months, Kyowa Kirin Co generated revenue of $511B at a net margin of 14.3%. Revenue grew 13.1% year over year. It earns a return on equity of 8.5%. The stock trades on a trailing P/E of 19.5. Fundamentals as of Jul 17, 2026
Our scenario range runs from $9.18 (bear case) to $19.85 (bull case); at $16.00, the current price sits within that range. Bear and bull are the same models run on conservative and optimistic assumptions (margins, growth, valuation multiples), so a plausible valuation range, not a price target. The share trades about 18% below its 52-week high and 13% above its 52-week low, currently below its 200-day average. For context, the median of 10 Healthcare peers we cover trades at -49% fair-value upside, at -1%, KYKOY screens cheaper than that median.
Fair Value models
Each model estimates fair value its own way; the Fair Value above is the evidence-weighted blend. Evidence (0–100) measures how completely this model’s inputs are available: well-fed models carry more weight in the blend. The spread across models is intentional, each one stresses a different value driver; dividend models, for instance, come out structurally low when payout is small.
All 24 models by family
Widest divergence: Multiples ($16.91) versus Growth DCF ($4.00). Highest evidence: Growth DCF (72).
Key figures & financial health
More key figures
Figures from reported company fundamentals · as of Jul 17, 2026. TTM = trailing twelve months.
Quality Score breakdown
Of which business quality 56 · Market factors (momentum, volatility) 45
Non-valuation factor families (profitability, growth, cashflow, financial strength, momentum …), each academically grounded. Valuation itself sits in the Fair Value and is deliberately excluded here to avoid double-counting.
About the company
Kyowa Kirin Co., Ltd. engages in the research, development, manufacturing, and marketing of pharmaceuticals in Japan, the Americas, Europe, Asia, and internationally.
Full company description
Kyowa Kirin Co., Ltd. engages in the research, development, manufacturing, and marketing of pharmaceuticals in Japan, the Americas, Europe, Asia, and internationally. The company offers Ziftomenib, an oral menin inhibitor for the treatment of adult relapsed or refractory and acute myeloid leukemia with a nucelophosmin1 mutation; and Lumicef for the treatment of palmoplantar pustulosis. It also develops KHK4083/AMG 451 rocatinlimab, which is in Phase III clinical trial for the treatment of moderate to severe atopic dermatitis and prurigo nodularis; KK8398 infigratinib, which is in Phase III clinical trial for the treatment of achondroplasia; OTL-203, which is in Phase III clinical trial for the treatment of hurler syndrome; KHK4951 tivozanib, which is in Phase II clinical trial for the treatment of diabetic macular edema and neovascular age-related macular degeneration; and OTL-201, which is in Phase II clinical trial for the treatment of sanfilippo syndrome type A. In addition, the company is involved in the development of KK2260 and KK2269, which are both in Phase I clinical trials for the treatment of advanced or metastatic solid tumors; KK2845, which is in Phase I clinical trial for the treatment of acute myeloid leukemia; KK3910, which is in Phase I clinical trial for the treatment of essential hypertension; KK4277, which is in Phase I clinical trial for the treatment of systemic/cutaneous lupus erythematosus; and KK8123, which is in Phase I clinical trial for the treatment of X-linked hypophosphatemia. It has a partnership with La Jolla Institute for Immunology for research in disease areas; AstraZeneca for severe asthma treatment; and AMGEN for therapeutic drugs development. The company was formerly known as Kyowa Hakko Kirin Co., Ltd. and changed its name to Kyowa Kirin Co., Ltd. in July 2019. Kyowa Kirin Co., Ltd. was incorporated in 1949 and is headquartered in Chiyoda, Japan. The company operates as a subsidiary of Kirin Holdings Company, Limited.
Company description, as reported by the company or data provider.
Revenue & earnings trend
FY2021 – FY2025 · reported fiscal years
Kyowa Kirin Co reported revenue of $497B in FY2025 versus $352B in FY2021, a compound +9.0%/yr. Reported net income was $67.0B in FY2025, compounding +6.4%/yr from FY2021.
Watch KYKOY: get an alert when its fair value changes →
Recent news
External third-party headlines (Yahoo Finance, Reuters and others), not an editorial selection.
- Kyowa Kirin Non-GAAP EPS of ¥103.26, revenue of ¥263.63B; reaffirms FY 2026 outlook
- FDA Selects Kyowa Kirin for PreCheck Pilot Program to Accelerate Manufacturing Timelines and Enhance Supply Chain Resilience
Peer Group
Drug Manufacturers - Specialty & Generic · 626 stocks
How this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.
Valuation Multiples vs Drug Manufacturers - Specialty & Generic median · lower = cheaper
Snowflake
Five quick dimensions, each 0 to 100: VALUE (fair-value potential), FUTURE (revenue growth), PAST (return on equity), HEALTH (low debt), DIVIDEND (yield). Green = this stock, grey = typical sector peer.
Values & ESG
Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.
ESG scores are not available for this stock yet. Values and ESG data are contextual and can differ between providers.
Similar stocks
10 more Drug Manufacturers - Specialty & Generic stocks, each showing price versus our Fair Value estimate (as of Jul 17, 2026).
| Stock | Price | Fair Value | vs Fair Value |
|---|---|---|---|
| Jiangsu Hengrui Pharmaceuticals Co 600276 | ¥53.19 | ¥25.94 | -51% |
| Sun Pharmaceutical Industries Limited SUNPHARMA | ₹1,933 | ₹989.50 | -49% |
| Divi's Laboratories Limited DIVISLAB | ₹7,316 | ₹1,943 | -73% |
| Torrent Pharmaceuticals Limited TORNTPHARM | ₹4,763 | ₹1,329 | -72% |
| PharmaEssentia Corporation 6446 | 1,285 TWD | 221.01 TWD | -83% |
| Cipla Limited CIPLA | ₹1,439 | ₹1,001 | -30% |
| Zydus Lifesciences Limited ZYDUSLIFE | ₹1,151 | ₹703.32 | -39% |
| Lupin Limited LUPIN | ₹2,443 | ₹2,477 | +1% |
| Mankind Pharma Limited MANKIND | ₹2,484 | ₹983.11 | -60% |
| Dr. Reddy's Laboratories Limited DRREDDY | ₹1,211 | ₹874.79 | -28% |
Compare Kyowa Kirin Co with another stock
Price, fair value, quality and upside side by side.
Explore undervalued stocks
More undervalued Healthcare stocks →
Frequently asked questions
Is Kyowa Kirin Co (KYKOY) overvalued or undervalued?
What is the fair value of KYKOY?
What is the quality score of KYKOY?
What is the revenue of Kyowa Kirin Co (KYKOY)?
What is the net profit margin of KYKOY?
Does Kyowa Kirin Co pay a dividend?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data, nothing guessed.
Track Kyowa Kirin Co and try Pro for 14 days
One email gets you 14 days of full Pro (review alerts, the 35,000+ stock screener, the diversification check) plus the monthly Top-25 report of the most undervalued quality stocks. No card, cancel anytime.
Zero risk: nothing is ever charged. After 14 days you decide whether to stay.